| Abstrakt: |
Applied StemCell, Inc., a leading CRO/CDMO recognized for its proprietary TARGATT gene editing technology and expertise in stem cells and cell therapy development, is pleased to announce the addition of two accomplished professionals to its C-level executive team: George Hong (Chief Commercial Officer) and Timothy J. Largen (Chief Operating Officer). The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization. [ABSTRACT FROM PUBLISHER] |
